| 000 | 01632 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250517160638.0 | ||
| 264 | 0 | _c20180716 | |
| 008 | 201807s 0 0 eng d | ||
| 022 | _a1578-2190 | ||
| 024 | 7 |
_a10.1016/j.ad.2016.12.023 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBonanad, C | |
| 245 | 0 | 0 |
_aClinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease. _h[electronic resource] |
| 260 |
_bActas dermo-sifiliograficas _cNov 2017 |
||
| 300 |
_a800-808 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xepidemiology |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperlipidemias _xchemically induced |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMeta-Analysis as Topic |
| 650 | 0 | 4 |
_aMetabolic Syndrome _xepidemiology |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aPsoriasis _xdiagnosis |
| 650 | 0 | 4 |
_aRetinoids _xadverse effects |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aGonzález-Parra, E | |
| 700 | 1 | _aRivera, R | |
| 700 | 1 | _aCarrascosa, J M | |
| 700 | 1 | _aDaudén, E | |
| 700 | 1 | _aOlveira, A | |
| 700 | 1 | _aBotella-Estrada, R | |
| 773 | 0 |
_tActas dermo-sifiliograficas _gvol. 108 _gno. 9 _gp. 800-808 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ad.2016.12.023 _zAvailable from publisher's website |
| 999 |
_c27274043 _d27274043 |
||